About

Bharat Immunologicals & Biologicals Corporation Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹35 Cr

P/E

—

P/B

0.3×

Dividend yield

0%

ROE

-12.6%

ROCE

-5.4%

Debt / equity

0.74

OPM

-6.4%

EPS (TTM)

₹-4.0

Book value

₹24.4

52-week high

₹22.0

52-week low

₹8.2

₹8.2-61.4%1Y

Beta

1.38

Amplifies index moves

Volatility (1y)

45.9%

Annualised, daily returns

RSI (14)

7

Oversold territory

Rel. strength (1y)

-70.6%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of -39.6% (3-yr avg)
−Revenue shrank over the last 5 years (-8.8% a year)
−Weak interest coverage of -0.7×
−Trading 62.7% below its 52-week high

Research score

Structured signal from quality, growth, valuation and momentum.

28/100

Business quality: 13
Growth: 0
Valuation: 100

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
	128	124	35	84	67	85	78
COGS	-116	-97	-30	-73	69	81	60
Gross profit	—	—	—	—	-2	4	19
	250	210	73	166	8	25	24
Operating profit (EBITDA)	-5	11	-8	-9	-10	-21	-5
OPM %	-4.3%	9%	-24.4%	-10.6%	-15.6%	-24.5%	-6.4%
Depreciation	1	0	0	0	0	0	0
Interest	2	3	—	1	5	5	6
	1	1	2	3	1	2	1
Profit before tax	-8	9	-8	-8	-14	-24	-10
Tax	-2	3	-3	-3	-4	-6	-1
Tax %	-29.4%	29.7%	-34.6%	-31.1%	-28.1%	-25.2%	-9.6%
	-5	7	-5	-6	-10	-18	-9
PAT margin %	-4.2%	5.4%	-14.9%	-6.7%	-15.3%	-21.2%	-11.2%
EPS (₹)	-1.2	—	-1.2	-1.9	-2.4	—	—
EPS adjusted (₹)	—	1.6	-1.2	-1.3	-2.4	-4.2	-2
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Equity capital	43	43	43	43	43	43
Reserves	-8	-6	-13	-23	-9	62
	9	0	32	3	27	78
	24	16	62	103	43	29
Total equity & liabilities	68	53	125	127	104	213
	6	5	5	4	4	84
CWIP	0	0	0	0	32	32
Investments	0	0	—	—	0	0
	63	48	120	122	68	97
Total assets	68	53	125	127	104	213

₹ Cr	Mar 2021	Mar 2022
	12	-42
	1	1
	-12	45
Net cash flow	0	3
Free cash flow	—	—
CFO / Operating profit %	—	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Margins
Gross margin %	—	—	—	—	-3.2%	4.8%	23.9%
EBITDA margin %	-4.3%	9%	-24.4%	-10.6%	-15.6%	-24.5%	-6.4%
EBIT margin %	-5.1%	8.7%	-25.6%	-11%	-15.9%	-24.7%	-6.6%
PAT margin %	-4.2%	5.4%	-14.9%	-6.7%	-15.3%	-21.2%	-11.2%
Working capital
Receivable days	—	38	167	318	96	0	5
Inventory days	—	73	15	57	274	61	222
Payable days	—	25	4	174	230	66	5
NWC days	—	86	178	201	140	-6	222
Leverage
Current ratio	—	1.49	3.05	1.12	0.92	0.53	0.65
Debt to EBITDA	—	0.84	—	—	—	—	—
Debt to equity	—	0.27	0	1.05	0.15	0.8	0.74
Interest coverage	-2.2	4.5	—	-4.4	-2	-4.1	-0.7
Asset turnover	—	1.82	0.65	0.67	0.53	0.82	0.37
Return ratios
Return on assets %	—	9.8%	-9.7%	-4.4%	-8.1%	-17.4%	-4.1%
Return on capital employed %	—	31.9%	-18.7%	-16.9%	-30.2%	-58.9%	-5.4%
Return on equity %	—	19%	-13.8%	-18.1%	-49.9%	-53.2%	-8.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	59.25%	59.25%	59.25%	59.25%	59.25%	59.25%	59.25%	59.25%	59.25%	59.25%	59.25%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Public	40.75%	40.75%	40.75%	40.75%	40.75%	40.75%	40.75%	40.75%	40.75%	40.75%	40.75%

Promoter holding up 0 percentage points since Sep 2021.

9 deals · 23 Dec 2022 – 27 Mar 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
27 Mar 2025	PRIYA MANAVADARIYA	Bulk	BSE	Sell	3,00,000	₹20.25	₹0.61 Cr
27 Mar 2025	ARVINDBHAI JETHABHAI MORI	Bulk	BSE	Buy	3,00,000	₹20.25	₹0.61 Cr
7 Jan 2025	NK SECURITIES RESEARCH PVT. LTD.	Bulk	BSE	Sell	2,48,928	₹33.80	₹0.84 Cr
7 Jan 2025	NK SECURITIES RESEARCH PVT. LTD.	Bulk	BSE	Buy	2,48,928	₹33.74	₹0.84 Cr
6 Jan 2025	PRIYA MANAVADARIYA	Bulk	BSE	Buy	2,32,327	₹30.10	₹0.70 Cr
27 Dec 2022	MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Bulk	BSE	Buy	4,97,590	₹44.50	₹2.21 Cr
27 Dec 2022	MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Bulk	BSE	Sell	3,40,168	₹44.49	₹1.51 Cr
23 Dec 2022	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Sell	2,20,559	₹44.85	₹0.99 Cr
23 Dec 2022	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Buy	2,20,559	₹44.12	₹0.97 Cr

1–9 of 9

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. SUDHANSHU VRATINon-Executive - Independent Director-Chairperson
Uttam Kumar SinghChief Financial Officer
Mr. DHANANJAY KUMAR TIWARYExecutive Director-MD
Mrs. ALKA SHARMANon-Executive - Independent Director
Mrs. MADHU DIKSHITNon-Executive - Independent Director
Mr. MOHD ASLALNon-Executive - Independent Director
Mr. PANKAJ KUMARNon-Executive - Independent Director
Sandip Kumar LalCompany Secretary and Compliance Officer
SANDIP KUMAR LALDgm & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Bharat Immunologicals & Biologicals Corporation Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

2

The Exchange has sought clarification from Bharat Immunologicals & Biologicals Corporation Ltd on September 30, 2026 with reference to significant movement in price, in order to ensure ....30 Sept 2026 · Clarification
Pursuant to the Regulation 30 and other applicable Regulation(s) of SEBI LODR, It is informed that the Government of India has approved the closure of Bharat Immunologicals and Biologicals ....17 Sept 2026 · Winding-up

Annual reports

25

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

No events on record

Corporate actions, results dates and filings will appear here once ingested.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

2 announcementsExport CSV

30 Sept 2026, 6:15 pmCompany Update

Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd

Clarification

17 Sept 2026, 11:44 amCompany Update

Announcement under Regulation 30 (LODR)-Winding-up

Winding-up PDF

Date	Category	Subject	Filing
30 Sept 2026, 6:15 pm	Company Update Clarification	Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd	—
17 Sept 2026, 11:44 am	Company Update Winding-up	Announcement under Regulation 30 (LODR)-Winding-up	PDF

Loading announcements…

Bharat Immunologicals & Biologicals Corporation Ltd

Bharat Immunologicals & Biologicals Corporation Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

No events on record

Announcements

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

No events on record

Compounded sales growth

Stock price CAGR

Return on equity

Bharat Immunologicals & Biologicals Corporation Ltd

Bharat Immunologicals & Biologicals Corporation Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

No events on record

Announcements

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

No events on record

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Stock price CAGR

Return on equity